Mirena® IUD’s Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

Inclusion Criteria:

Women between 35 and 50 years of age (inclusive)
Women who will be scheduled to undergo an RRSO or RRs
Women who will have at least one fallopian tube removed for risk-reducing reasons (with or without removal of ovar(ies))
Women who are willing to have a Mirena® IUD inserted at least prior to risk-reducing surgery or who already have the Mirena® in place
Women using non-hormonal forms of contraception (Note: If a copper IUD is being used, the IUD must be removed prior to or at time of Mirena insertion.)

Exclusion Criteria:

Any medical contraindication to use of a Mirena® IUD, including:

Pregnancy (a pregnancy test is required prior to study entry)
Known uterine anomaly that distorts the shape of the uterine cavity
Acute pelvic inflammatory disease
Postpartum endometritis or endometrial infection
Known or suspected uterine or cervical neoplasia
Known history or suspected breast cancer or other progestin-sensitive cancer
Uterine bleeding of unknown etiology.
Untreated acute cervicitis, vaginitis, or other lower genital tract infections
Acute liver disease or liver tumor (benign or malignant)
Use of tamoxifen, raloxifene, or chemotherapy within the previous 6 months
Positive pregnancy test
Breastfeeding
Use of a copper IUD if the patient is not willing to have it removed prior to surgery and replaced with a Mirena® IUD